Clinical Guidelines Alerts August 2023 Banner
  • Management of Pregnancy
    • Society:Veterans Health Administration / Department of Defense (VHA/DoD)
    • Published:August 1, 2023
  • Use of Prolonged-Infusion Beta-Lactam Antibiotics
    • Society:Cystic Fibrosis Foundation (CFF); Infectious Diseases Society of America (IDSA); Society of Critical Care Medicine (SCCM); Society of Infectious Diseases Pharmacists (SIDP); American College of Clinical Pharmacy (ACCP)
    • Published:August 24, 2023
  • PET/MRI in Oncology
    • Society:Society of Nuclear Medicine and Molecular Imaging (SNMMI)
    • Published:August 25, 2023
  • Postdural Puncture Headache
    • Society:American Society of Regional Anesthesia and Pain Medicine (ASRA); Society for Obstetric Anesthesia and Perinatology (SOAP)
    • Published:August 15, 2023
FDA Drug Approvals August 2023 Banner
  • Lonsurf (Taiho Oncology)New Indication
    • With bevacizumab for patients with metastatic colorectal cancer (CRC) who have previously undergone treatment with fluoropyrimidine, oxaliplatin, and irinotecan-based chemotherapy as well as an anti-VEGF biological therapy and an anti-EGFR if tumors are RAS wild-type.
  • Zurzuvae (Sage Therapeutics / Biogen)
    • For adults with postpartum depression (PPD).
  • Izervay (Astellas) 
    • Treatment of geographic atrophy (GA) secondary to age-related macular degeneration (AMD).
  • Talvey (Janssen) 
    • Treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 antibody.
  • Akeega (Janssen)
    • Treatment of adult patients with deleterious or suspected deleterious BRCA-positive mCRPC, as detected by an FDA-approved test.
  • Elrexfio (Pfizer) 
    • Treatment of adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.
  • Daxxify (Revance Therapeutics) 
    • Treatment of cervical dystonia in adults.
  • Hepzato Kit (VDelcath System)
    • Hepatic Delivery System for the Treatment of Unresectable Hepatic-Dominant Metastatic Uveal Melanoma.
  • Sohonos (Ipsen) 
    • For the reduction in volume of new heterotopic ossification in adults and pediatric patients aged 8 years and older for females and 10 years and older for males with fibrodysplasia ossificans progressiva (FOP).
  • Veopoz (Regeneron)
    • Treatment of adult and pediatric patients 1 year of age and older with CHAPLE disease, also known as CD55-deficient protein-losing enteropathy.
  • Ingrezza (Neurocrine Biosciences)New Indication
    • Treatment of adults with chorea associated with Huntington’s disease (HD).
  • Eyelea HD (Regeneron)New Formulation 
    • Treatment of patients with wet age-related macular degeneration (wAMD), diabetic macular edema (DME) and diabetic retinopathy (DR).
  • Abrysvo (Pfizer)
    • Prevention of LRTD and severe LRTD caused by RSV in infants from birth up to six months of age by active immunization of pregnant individuals at 32 through 36 weeks gestational age.
  • Tyruko (Sandoz)Biosimilar to Tysabri 
    • Treatment of adults with relapsing forms of multiple sclerosis (MS).
  • Veklury (Gilead)
    • To treat COVID-19 in people with mild, moderate and severe hepatic impairment.
  • Reblozyl (Bristol Myers Squibb)Expanded Indication
    • Treatment of anemia without previous erythropoiesis stimulating agent use (ESA-naïve) in adult patients with very low- to intermediate-risk myelodysplastic syndromes (MDS) who may require regular red blood cell (RBC) transfusions.
  • Ilaris (Novartis)New Indication
    • Treatment of gout flares in adults who cannot be treated with NSAIDs, colchicine, or repeated courses of corticosteroids.

Copyright © 2023 Guideline Central, All rights reserved.